Stocktoria
Niagen Bioscience, Inc. NAGE
Niagen Bioscience, Inc. (NAGE) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $129.4M at a 13.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.723 |
| Retained earnings / assets | -1.546 |
| EBIT / assets | 0.153 |
| Equity / liabilities | 2.562 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| NAGE | Niagen Bioscience, Inc. | 5/9 | 3.42 | 15.7 | +29.9% |
| NAII | NATURAL ALTERNATIVES INTERNATIONAL INC | 5/9 | 3.07 | — | +14.1% |
| MTEX | MANNATECH INC | 2/9 | -1.37 | — | -8.3% |
| MRMD | MARIMED INC. | 4/9 | -1.76 | — | +1.3% |
| GLAS | Glass House Brands Inc. | 3/9 | -1.45 | — | -9.4% |
| BTMD | biote Corp. | 5/9 | 0.92 | 2.5 | -2.5% |
| CRON | Cronos Group Inc. | 6/9 | — | — | +19.5% |
About Niagen Bioscience, Inc.
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
FAQ
Is NAGE financially healthy?
Niagen Bioscience, Inc.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does NAGE pay a dividend?
No, Niagen Bioscience, Inc. does not currently pay a dividend.
How profitable is NAGE?
In FY2025, Niagen Bioscience, Inc. had a net margin of 13.4% and a return on equity of 22.7%.
What is NAGE's P/E ratio?
Niagen Bioscience, Inc.'s trailing price-to-earnings (P/E) ratio is about 15.7×, based on its latest annual earnings.
What is the analyst price target for NAGE?
The average Wall-Street price target for Niagen Bioscience, Inc. is $12.60, about 311.8% above the recent price, from 5 analysts.
Is NAGE a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Niagen Bioscience, Inc.: a Piotroski F-score of 5/9, an Altman Z″ in the safe zone, a P/E of about 15.7×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.